Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work
ConclusionScreening for mutations in both KRAS and NRAS may provide the most cost-effective approach to patient selection.
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research
More News: Cancer | Cancer & Oncology | Colorectal Cancer | Economics | Erbitux | Genetics | Health Management | Study | Toxicology